Lunit INSIGHT DBT:
AI-Powered Software
for 3D Tomosynthesis

Analyze multi-slice exams with AI that highlights suspicious findings, speeds up review, and reduces reading fatigue.

Logo 1
Logo 2
This product is not available for sale or distribution in all countries.
Detect with precision

Detect with precision

Suspicious lesions are assigned an abnormality score and clearly marked, supporting consistent, confident decision-making.
Classify with clarity

Classify with clarity

Classify lesions as masses (including asymmetries and distortions) or calcifications with AI-enhanced guidance.
Navigate faster, easier

Navigate faster, easier

Jump to key slices automatically with viewer-integrated AI guidance—no more manual scrolling through stacks.

Seamless AI Support for 3D Mammography Interpretation

Lunit INSIGHT DBT (3D) AI-powered mammography software enhances lesion detection in digital breast tomosynthesis exams, helping radiologists interpret complex cases with greater precision.

It delivers AI-guided navigation during image review and is built for seamless integration into PACS and viewers. This reduces reading time*, simplifies slice selection, and supports single and double-reading workflows, helping manage high case volumes and reduce radiologist fatigue.

*Eun Kyung Park, et al., Impact of AI for Digital Breast Tomosynthesis on Breast Cancer Detection and Interpretation Time, Radiology Artificial Intelligence, 2024.

Seamless AI Support for 3D Mammography Interpretation

Clinically Validated to Improve 3D Breast Cancer Detection

Bar chart showing AI-assisted mammography achieving consistent 93% accuracy across both fatty and dense breast types.

Consistent high performance across breast types

Lunit INSIGHT DBT enhances breast cancer detection in both fatty and dense breasts. By supporting more consistent interpretation across tissue types, it helps radiologists catch subtle or early-stage cancers that are often missed in standard screening.¹

  1. Park EK, Kwak SK, Lee W et al. Impact of AI for Digital Breast Tomosynthesis on Breast Cancer Detection and Interpretation Time. Radiology Artificial Intelligence, 2024.

Fewer false positives and callbacks

With improved specificity, Lunit’s AI helps reduce unnecessary recalls*, supporting more confident reads and lowering patient anxiety. Radiologists can interpret DBT exams with fewer interruptions and clearer decision support.

*Park EK et al, Impact of AI for Digital Breast Tomosynthesis on Breast Cancer Detection and Interpretation Time. Radiology Artificial Intelligence, Volume 6: Number 3 - 2024.

Line graph showing AI-assisted mammography increasing specificity and reducing recall rates compared to radiologists alone.
Mammogram comparison showing interval cancer detected by AI-assisted mammography that was missed in prior screening.

Earlier detection of interval cancers

*Bahl M, Langarica S, Lamb LR, et al. AI to Reduce the Interval Cancer Rate of Screening Digital Breast Tomosynthesis. Radiology. 2025

Interpretable AI for decision support

Each suspicious lesion is assigned an abnormality score (0–100), helping quantify malignancy likelihood. Location is clearly marked using heatmaps or contours, and lesion types—such as masses (including architectural distortion and asymmetry), and calcifications—are identified for targeted interpretation. The best slice for lesion visualization is marked on the navigation bar for quick review.

Annotated mammogram showing AI-assisted mammography highlighting lesions with heatmaps and malignancy scores for diagnostic decision support.
Radiologist using AI radiology software to analyze mammogram images.

Interpret 3D Mammograms with Speed and Precision

See how our AI-assisted mammography solution accelerates tomosynthesis review, highlights key findings, and improves cancer detection efficiency.

Frequently Asked Questions

Does a higher score mean a worse prognosis?

No. The AI-assisted mammography software is trained to predict the likelihood that a lesion is cancerous, not its severity, clinical implications, or treatment outcome. While invasive cancers may receive higher scores than noninvasive ones, that is not always the case. If the AI is confident that a malignant lesion exists, it assigns the score accordingly, regardless of subtype.

Note: The scale is not linear (e.g., a score of 90 is not three times more suspicious than a score of 30).